Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockUpcoming Result Date: Apr 26, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is currently trading at 197.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company specializing in Gynaecology, Orthopaedics, and Dermatology. It operates primarily in India, holding competitive positions in these key therapeutic areas. In FY26, the company experienced a 6% YoY revenue growth reaching ₹2,230 Mn, with an operational PAT increase of 12.5%. This demonstrates their continued profitability and resilience despite modest quarterly performance. The accumulation of a cash balance of ₹1,757 Mn indicates robust free cash flow generation, underscoring their strong financial position and capacity for strategic investment or distribution to shareholders. Jagsonpal focuses on maintaining strong brand equity. Its diversification into acquiring the Yash Pharma business has enhanced its portfolio, paving the path for further growth in attractive market segments. Innovations in their product pipeline and adherence to market demands are supported by partnerships and strategic product launches, strengthening their competitive edge in the pharmaceutical sector.
Over the past 52 weeks, Jagsonpal Pharmaceuticals Ltd has traded between a low of ₹154.90 and a high of ₹301.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Jagsonpal Pharmaceuticals Ltd has a market capitalization of approximately 1,244.42. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Jagsonpal Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.38 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,244.42 Cr, Jagsonpal Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Jagsonpal Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Jagsonpal Pharmaceuticals Ltd is 31.38. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board of Jagsonpal Pharmaceuticals has approved a buyback price of ₹250 per equity share through a tender offer.
The board of Jagsonpal Pharmaceuticals has approved a buyback of up to 16 lakh shares at a price of ₹250 per share, with a total maximum value of ₹40 crore. The buyback will be conducted through a tender offer.
Board Meeting - Results
Jagsonpal Pharmaceuticals scheduled a Board meeting on April 27, 2026 to consider and approve audited financial results for the quarter and year ended March 31, 2026 and to consider recommendation of dividend, if any.
Board Meeting - Results
Jagsonpal Pharmaceuticals scheduled a Board meeting on April 27, 2026 to consider and approve audited financial results for the quarter and year ended March 31, 2026 and to consider recommendation of a dividend, if any.
Bearish
3
Neutral
8
Bullish
3
Bearish
6
Neutral
8
Bullish
32
Bearish
3
Neutral
0
Bullish
29
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1394.40 | 1,352 Cr | 33.18 | 5.93 | 0.00 | 18.96 | 18.07 | 8.50 | ||
14.04 | 1,283 Cr | 18.00 | 3.39 | 0.00 | 16.66 | 22.00 | 15.12 | ||
1429.05 | 1,257 Cr | 28.62 | 3.72 | 0.47 | 12.98 | 9.93 | 6.29 | ||
190.30 | 1,244 Cr | 31.38 | 4.92 | 1.33 | 17.30 | 21.58 | 13.68 | ||
615.00 | 1,232 Cr | 14.02 | 1.72 | 0.29 | 11.18 | 15.34 | 10.28 | ||
132.10 | 1,147 Cr | 5.55 | 0.84 | 0.00 | 2.27 | 1.19 | 16.09 | ||
1820.00 | 1,140 Cr | 28.07 | 4.45 | 0.03 | 22.85 | 26.16 | 7.04 | ||
| Median: 7 Co. | — | 615.00 | 1,244 Cr | 28.07 | 3.72 | 0.03 | 16.66 | 18.07 | 10.28 |
Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company specializing in Gynaecology, Orthopaedics, and Dermatology. It operates primarily in India, holding competitive positions in these key therapeutic areas.
In FY26, the company experienced a 6% YoY revenue growth reaching ₹2,230 Mn, with an operational PAT increase of 12.5%. This demonstrates their continued profitability and resilience despite modest quarterly performance.
The accumulation of a cash balance of ₹1,757 Mn indicates robust free cash flow generation, underscoring their strong financial position and capacity for strategic investment or distribution to shareholders.
Jagsonpal focuses on maintaining strong brand equity. Its diversification into acquiring the Yash Pharma business has enhanced its portfolio, paving the path for further growth in attractive market segments.
Innovations in their product pipeline and adherence to market demands are supported by partnerships and strategic product launches, strengthening their competitive edge in the pharmaceutical sector.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,244 Cr
Low Risk
31.4
32.2
0.7
4.9
301.80
154.90
Sales CAGR
Profit CAGR
ROE
ROCE
